

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING

Reference is made to the circular (the “**Circular**”) of RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the “**Company**”) incorporating, amongst others, the notice of 2025 second extraordinary general meeting (the “**EGM**”) dated March 17, 2025. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

ATTENDANCE AT THE EGM

The Board is pleased to announce that the EGM was held at Room 6134, Phase III Building of the Company at 58 Middle Beijing Road, Yantai Development Zone, Yantai Area of Shandong Pilot Free Trade Zone, the PRC on Wednesday, April 2, 2025 at 2:00 p.m.

The attendance of the EGM was as follows:

Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against resolution)	Number of Shares present (in person or by proxy)	Approximate % of Shares present (in person or by proxy)
A Shares	354,750,844	199,699,437	36.6871
H Shares	189,581,239	18,567,337	3.4110
Total	544,332,083	218,266,774	40.0981

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolution proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on the resolution proposed at the EGM.

The EGM was convened by the Board. All Directors attended the EGM.

POLL RESULTS OF THE EGM

The poll results of the EGM were as follows:

Ordinary Resolution		Number of votes and percentage of the total voting shares at the EGM			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the appointment of Mr. Wen Qingkai as an executive director of the Company.	217,911,121 99.8371%	352,645 0.1616%	3,008 0.0014%	Yes

As more than half of the votes casted in favour of the ordinary resolution numbered 1 above, the resolution was duly passed.

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM. Two representatives of the Shareholders, two lawyers of King & Wood Mallesons and one supervisor of the Company participated in the scrutiny of the poll results.

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEE

At the EGM, Mr. Wen Qingkai (“**Mr. Wen**”) was appointed as an executive Director of the second session of the Board. The appointment of Mr. Wen shall come into effect immediately after the conclusion of the EGM and until the expiry of the term of the second session of the Board. Mr. Wen has also been appointed as a member of the Strategy Committee with effect from his appointment as an executive Director at the EGM until the expiry of the term of the second session of the Board. For the biographical details of Mr. Wen, please refer to the announcement of the Company dated March 14, 2025. As at the date of this announcement, there has been no change in such information.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, the PRC
April 2, 2025

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* For identification purposes only